{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:10Z","timestamp":1786994410008,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.msard.2021.103118","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T02:37:31Z","timestamp":1625020651000},"page":"103118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"54","author":[{"given":"Tiziana","family":"Carandini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Azzimonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bozzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Scarpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Margherita","family":"Pietroboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103118_bib0001","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/brain\/awh550","article-title":"Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice","volume":"128","author":"Bannerman","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103118_bib0002","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2018.08.008","article-title":"Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis","volume":"25","author":"Bensi","year":"2018","journal-title":"Multip. Sclerosis Relat. Disord."},{"key":"10.1016\/j.msard.2021.103118_bib0003","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ana.25411","article-title":"Brain and cord imaging features in neuromyelitis optica spectrum disorders: MRI and NMOSD Diagnosis","volume":"85","author":"Cacciaguerra","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103118_bib0004","article-title":"Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder","author":"Cai","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103118_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116430","article-title":"Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: a Chinese cohort study","volume":"405","author":"Chen","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103118_bib0006","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103118_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Systematic Rev."},{"key":"10.1016\/j.msard.2021.103118_bib0008","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Higgins JPT, Altman DG, 2019. Chapter 10: analysing data and undertaking meta-analyses., in: Cochrane Handbook for Systematic Reviews of Interventions Version 6.0.","DOI":"10.1002\/9781119536604.ch10"},{"key":"10.1016\/j.msard.2021.103118_bib0009","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.neurad.2019.06.001","article-title":"MRI features of demyelinating disease associated with anti-MOG antibodies in adults","volume":"46","author":"Den\u00e8ve","year":"2019","journal-title":"J. Neuroradiol."},{"key":"10.1016\/j.msard.2021.103118_bib0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103118_bib0011","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/rg.2018170141","article-title":"Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis","volume":"38","author":"Dutra","year":"2018","journal-title":"Radiographics"},{"key":"10.1016\/j.msard.2021.103118_bib0012","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in Japan","volume":"126","author":"Ishikawa","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2021.103118_bib0013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammat."},{"key":"10.1016\/j.msard.2021.103118_bib0014","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammat."},{"key":"10.1016\/j.msard.2021.103118_bib0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103118_bib0016","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103118_bib0017","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103118_bib0018","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/1352458510376640","article-title":"Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity","volume":"16","author":"Kim","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103118_bib0019","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103118_bib0020","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103118_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis optica spectrum disorder and Anti-MOG syndromes","volume":"7","author":"Lana-Peixoto","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.msard.2021.103118_bib0022","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"The Lancet"},{"key":"10.1016\/j.msard.2021.103118_bib0023","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/WCO.0000000000000813","article-title":"Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases","volume":"33","author":"Mader","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2021.103118_bib0024","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2021.103118_bib0025","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103118_bib0026","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2021.103118_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","author":"Salama","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103118_bib0028","article-title":"MRI characteristics of MOG-Ab associated disease in adults: an update","author":"Shor","year":"2020","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2021.103118_bib0029","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3341\/kjo.2017.31.1.71","article-title":"Initial pattern of optic nerve enhancement in korean patients with unilateral optic neuritis","volume":"31","author":"Son","year":"2017","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.msard.2021.103118_bib0030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103118_bib0031","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103118_bib0032","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103118_bib0033","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.msard.2021.103118_bib0034","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821003850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821003850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:43Z","timestamp":1761901003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821003850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":34,"alternative-id":["S2211034821003850"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103118","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103118"}}